Drug Store News - FDA gives clearance to Eisai/Janssen to expand Aciphex indication
The Food and Drug Administration has approved expanded use for Aciphex (rabeprazole sodium), a protonpump inhibitor, as a treatment for daytime and nighttime heartburn and other symptoms associated with gastro-esophageal reflux disease. Aciphex was discovered and developed by Eisai Co. and is co-marketed in the United States by Eisai and Janssen Pharmaceutica.
Related Results
AciphexAciphexAciphex approvalAciphex approvedEisai, Janssen Revamp Aciphex Packaging
An estimated 60 million Americans experience heartburn, the most common manifestation of symptomatic GERD, on a monthly basis.
COPYRIGHT 2002 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
